24 August 2016 - The PBAC will consider 66 submissions (34 major & 32 minor) at its next scheduled meeting in November.

Table 1. Submissions by medicine type

PBS = Pharmaceutical Benefits Scheme; NIP = National Immunisation Program; LSDP = Life Saving Drugs Program. * Nutritional supplements; ** Section 100 or LSDP

The Committee will also consider five reports from the Drug Utilisation Subcommittee (DUSC) for medicines for

• Fungal infection (7 medicines)
• Schizophrenia (11 medicines)
• Early termination of pregnancy (1 medicine)
• Osteoporosis (12 medicines)
• Hepatic encephalopathy (1 medicine)
• Androgen deficiency (3 medicines)

13 of the 66 submissions are for new medicines/vaccines (Table 2).

Table 2. Submissions by listing type

21 (32%) of the 66 submissions are resubmissions; most are for new listings or new indications (Table 3).

Table 3. Resubmissions by listing type

Just under a third of all submissions are for medicines in WHO ATC main group L (Table 4).

Table 4. Submissions by therapeutic area

MSD and Vitaflo are the leading applicants (Table 5).

Table 5. Submissions by applicant